How can a patient check whether Medicare covers GLP-1 treatment for obesity in 2026?

As of 2024, Medicare law prohibits Part D plans from covering weight loss drugs, but patients should check their 2026 plan formulary for any policy changes.

Why Medicare Currently Excludes Weight Loss Drugs

Federal law, specifically the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, established Medicare Part D but explicitly excluded certain classes of drugs from coverage. This list includes medications prescribed for anorexia, weight loss, or weight gain.

As a result, GLP-1 agonist medications like Wegovy (semaglutide) and Zepbound (tirzepatide), which are FDA-approved specifically for chronic weight management, are generally not covered by Medicare Part D or Medicare Advantage plans when used for this purpose.

This exclusion is a matter of federal statute and applies to all Part D plans nationwide. It is not a decision made by individual insurance companies, though they must adhere to this rule when designing their Medicare plan benefits.

How to Check Your Specific Medicare Plan for 2026

The most reliable way to check for coverage in 2026 is to use the official Medicare Plan Finder tool on Medicare.gov during the Annual Enrollment Period, which runs from October 15 to December 7, 2025. This tool provides the most current formularies for the upcoming year.

When evaluating plans, you must download and review the plan's 'Formulary' (list of covered drugs) and the 'Evidence of Coverage' (EOC) document. Search these documents for the specific GLP-1 medication you need, such as 'semaglutide' or 'tirzepatide'.

Pay close attention to any coverage rules listed next to the drug, such as 'Prior Authorization' (PA) or 'Quantity Limits' (QL). Even if a drug is listed, these restrictions can affect your ability to get it covered.

You can also call the member services number for any plan you are considering for 2026 and ask a representative directly if GLP-1 agonists are on the formulary for the treatment of obesity. Be sure to specify the indication is weight loss.

Potential Legislative Changes Affecting 2026 Coverage

The primary legislative effort to watch is the Treat and Reduce Obesity Act (TROA). If passed by Congress and signed into law, this bill would amend Medicare law to authorize Part D coverage for FDA-approved obesity treatments, including GLP-1 medications.

The Inflation Reduction Act (IRA) of 2022 allows Medicare to negotiate prices for certain high-cost drugs starting in 2026. However, the IRA does not override the existing statutory exclusion for weight loss drugs. A separate act of Congress, like TROA, would be required to enable coverage.

Patients should monitor news from reputable health policy sources or organizations like the Obesity Action Coalition for updates on the status of TROA or other similar legislation throughout 2025, as this would be the main driver of any large-scale coverage changes by 2026.

The 'Diabetes Exception' for GLP-1 Coverage

An important distinction exists for patients with type 2 diabetes. Medicare Part D plans do cover GLP-1 agonists like Ozempic, Rybelsus, and Mounjaro when prescribed for their FDA-approved indication of glycemic control in adults with type 2 diabetes.

In this scenario, weight loss is considered a secondary benefit of managing diabetes, not the primary reason for the prescription. Therefore, the statutory exclusion for weight loss drugs does not apply.

If you have a diagnosis of both obesity and type 2 diabetes, your physician may prescribe a GLP-1 for diabetes management. This treatment path is a standard, covered approach under most Medicare Part D plans, subject to plan-specific formularies and prior authorization requirements.

Alternatives if Medicare Lacks Coverage in 2026

If Medicare coverage for obesity medications is not available in 2026, patients have other avenues to explore. Manufacturer savings programs or patient assistance programs may be available, but many explicitly exclude patients with government-sponsored insurance like Medicare.

Another option is a physician-supervised weight loss program. GOAL.MD offers comprehensive programs that may include access to compounded medications, which are prescribed by a physician and prepared by licensed U.S. pharmacies to meet individual patient needs.

Compounded semaglutide and tirzepatide are not FDA-approved. However, they can be prescribed as part of a holistic [weight loss](/weight-loss) plan that includes medical supervision, nutrition, and lifestyle coaching to help you achieve your health goals safely and effectively.

Bottom Line

For 2026, checking for Medicare coverage of GLP-1s for obesity requires monitoring potential legislative changes like the Treat and Reduce Obesity Act and, most importantly, reviewing specific plan formularies in late 2025. As of today, federal law prevents Medicare Part D from covering these drugs solely for weight loss, though they are covered for patients with type 2 diabetes.

This article is for informational purposes only and does not constitute medical advice.

Generated from GOAL.MD's physician-reviewed source library. This page has not received its own physician review. Physician-supervised telehealth. More at goal.md/answers.